Which one is the best-comparison of three treatment modalities in membranous glomerulonephropathy?

Authors

  • Mohammed Fahad Khan Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Sherin M. Reji Department of Clinical Research, Manipal Hospitals, Bangalore, Karnataka, India
  • Nijin Samuel Raju Department of Clinical Research, Manipal Hospitals, Bangalore, Karnataka, India
  • Vishwanath Siddini Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Kishore Babu Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Rohan Augustine Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Ravi Jangamani Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Shilpa Shetty Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • G. K. Prakash Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Sanjay Rampure Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India
  • Sudarshan Ballal Department of Nephrology, Manipal Hospitals, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243368

Keywords:

Membranous Nephropathy, Rituximab, Tacrolimus

Abstract

Background: This retrospective study explores the efficacy of Modified Ponticelli, Rituximab and Tacrolimus in treating membranous nephropathy, focusing on remission rates.

Methods: This retrospective study analyzed 41 membranous nephropathy cases treated with Modified Ponticelli, Rituximab, or Tacrolimus. Statistical analyses included Kruskal-Wallis and Chi-Square tests to evaluate treatment responses, renal markers and remission outcomes, providing comprehensive insights into treatment efficacy.

Results: Modified Ponticelli demonstrated substantial reductions in proteinuria (-88.20%) and favorable increases in albumin (15.80%), outperforming Rituximab and Tacrolimus. Significant differences (p=0.0014) in remission outcomes underscore Modified Ponticelli's efficacy, with the highest complete remission rate (26.7%) and notable partial remission rate (73.3%). Rituximab (Complete 0%, Partial 46.2%) and Tacrolimus (Complete 15.4%, Partial 30.8%) exhibited lower rates.

Conclusions: In conclusion, Modified Ponticelli demonstrates superior efficacy in achieving both complete and partial remission in membranous nephropathy patients.

References

Canetta PA, Radhakrishnan J. The evidence-based approach to adult-onset idiopathic nephrotic syndrome. Front Pediatr. 2015;3:78.

Bomback AS, Appel GB. Updates on the treatment of idiopathic membranous nephropathy. Kidney Int. 2015;87(4):665-73.

Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563-79.

Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566-74.

Ponticelli C, Zucchelli P, Passerini P. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;320(1):8-13.

De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):421-30.

Fervenza FC, Cosio FG, Erickson SB. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73(1):117-25.

Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. GEMRITUX:A 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348-58.

Cui W, Lu X, Min X, Liu M, Guan S, Wang Y, et al. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. Braz J Med Biol Res. 2017; 23;50(4):5976.

Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, et al. STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986-98.

Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al. RI-CYCLO Investigators. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021;32(4):972-82.

Fervenza FC, Appel GB, Barbour SJ. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46.

Downloads

Published

2024-10-30

How to Cite

Khan, M. F., Reji, S. M., Raju, N. S., Siddini, V., Babu, K., Augustine, R., Jangamani, R., Shetty, S., Prakash, G. K., Rampure, S., & Ballal, S. (2024). Which one is the best-comparison of three treatment modalities in membranous glomerulonephropathy?. International Journal of Research in Medical Sciences, 12(11), 4175–4179. https://doi.org/10.18203/2320-6012.ijrms20243368

Issue

Section

Original Research Articles